Zeluka-LC Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic idiopathic urticaria. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks leukotriene D4 at the cysteinyl leukotriene receptor, mitigating bronchoconstriction, inflammation, and mucus production associated with allergic responses. The synergistic action of these agents provides comprehensive relief from both immediate histamine-mediated and delayed leukotriene-mediated allergic symptoms. Zeluka-LC is typically administered once daily, preferably in the evening, with or without food, to optimize patient compliance and therapeutic efficacy. It is contraindicated in patients with known hypersensitivity to either component. Caution is advised in individuals with hepatic or renal impairment, and potential drug interactions should be reviewed prior to initiation. Common adverse effects may include headache, fatigue, dry mouth, and gastrointestinal disturbances, which are generally mild and transient. Zeluka-LC Tablet offers an effective and convenient option for patients requiring dual-action therapy in allergic disease management.